INDUSTRY FOCUS Clinical stage CNS specialist leveraging 505(b)2 repurposing to accelerate INDs, presenting a partnerable path for collaborators seeking faster regulatory timelines and expanded CNS indications.

INDICATION EXPANSION Pipeline emphasis on reformulation and administration improvements creates opportunities to co-develop or license novel dosage forms for movement disorders and PBA, appealing to pharma seeking new delivery strategies and better patient compliance.

REGULATORY READY FDA IND clearance for MR-101 demonstrates regulatory momentum; potential sales angle includes leveraging prior FDA engagement to streamline partnerships, milestone-driven deals, and risk-sharing opportunities.

PARTNER NETWORK Experience collaborating with regulatory bodies and a lean, agile team suggests value in CRO, CDMO, and strategic alliance conversations to de-risk development stages and speed time-to-market.

FUTURE PIPELINE Early-stage CNS assets with a clear path to INDs indicate ongoing opportunities for licensing, co-development, or upfront collaboration deals with larger pharma seeking to augment CNS portfolios.